Metagenomi (MGX) to Release Quarterly Earnings on Tuesday

Metagenomi (NASDAQ:MGX - Get Free Report) is projected to issue its Q1 2025 quarterly earnings data before the market opens on Tuesday, May 13th. Analysts expect Metagenomi to post earnings of ($0.62) per share for the quarter.

Metagenomi (NASDAQ:MGX - Get Free Report) last released its earnings results on Monday, March 17th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.01). Metagenomi had a negative return on equity of 43.23% and a negative net margin of 134.27%. The firm had revenue of $9.61 million during the quarter, compared to analysts' expectations of $13.18 million. During the same period in the previous year, the firm posted ($20.05) earnings per share. On average, analysts expect Metagenomi to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Metagenomi Trading Down 4.7 %

MGX traded down $0.08 during trading on Friday, hitting $1.52. 198,161 shares of the company's stock were exchanged, compared to its average volume of 780,335. Metagenomi has a 1 year low of $1.23 and a 1 year high of $8.17. The firm has a market cap of $56.63 million, a P/E ratio of -0.58 and a beta of -0.65. The stock has a 50 day moving average price of $1.62 and a 200 day moving average price of $2.28.

Wall Street Analyst Weigh In

Several analysts have issued reports on MGX shares. Wells Fargo & Company cut their target price on shares of Metagenomi from $25.00 to $20.00 and set an "overweight" rating on the stock in a research note on Tuesday, March 18th. HC Wainwright reduced their target price on Metagenomi from $14.00 to $7.00 and set a "buy" rating for the company in a report on Thursday, April 3rd.

Hedge Funds Weigh In On Metagenomi

A hedge fund recently raised its stake in Metagenomi stock. Bank of America Corp DE increased its stake in Metagenomi, Inc. (NASDAQ:MGX - Free Report) by 482.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 21,113 shares of the company's stock after purchasing an additional 17,491 shares during the period. Bank of America Corp DE owned approximately 0.06% of Metagenomi worth $76,000 as of its most recent SEC filing.

Metagenomi Company Profile

Metagenomi, Inc, a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.